Vertex is very experienced when it comes to drug launches). In the latest earnings report, the company said its goals for this year include ensuring broad access for patients and doctors, so ...

What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this year: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ ...

“Mặc dù là giá thuốc đắt hơn so với bình thường ... Long Châu hiện ghi nhận giá niêm yết của thuốc Tamiflu là 69.000 đồng/ viên, 690.000 đồng một hộp. Theo BSCKI Nguyễn Thị Thủy, Phó ...

Nhan sắc cực ngọt ngào của cô nàng Hoàng Anh Ốc Chỉ trong khoảng 1 năm, pickleball tạo nên cơn sốt mạnh mẽ trong cộng đồng thể thao phong trào Việt Nam. Đặc biệt rất nhiều chị em phụ ...

Adrienne So is a senior commerce editor for WIRED, where she reviews health and fitness gear. She graduated from the University of Virginia with bachelor’s degrees in English and Spanish and ...

Vertex' portfolio has been steadily expanded with new product launches to cover the majority of CF mutations, and so it has been looking at new therapeutic categories – including T1D ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.